Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
27 hedge funds and large institutions have $71.9M invested in Sierra Oncology, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
4% more funds holding
Funds holding: 26 → 27 (+1)
12% less capital invested
Capital invested by funds: $81.9M → $71.9M (-$9.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.62M |
| 2 |
Millennium Management
New York
|
+$1.49M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$453K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$224K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$4.58M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$208K |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$86.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$68.5K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$1K |
SRRA Hedge Fund Activity: Q3 2020 in Review
27 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2020, worth a combined $71.9M — down 12% from $81.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SRRA positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $3.62M. The largest seller was VR Adviser, exiting entirely with an estimated $4.58M sold.
- 27 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2020, up from 26 in Q2 2020.
- Funds reported $71.9M of Sierra Oncology, Inc. Common Stock stock for Q3 2020, down 12% quarter-over-quarter.
- 3 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2020 and 2 closed out, a net change of +1 holder.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2020 was Ikarian Capital, an estimated $3.62M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2020 was VR Adviser, an estimated $4.58M sold.
Based on aggregated 13F filings for Q3 2020.